Showing results (1-10 of 397) with videos related to
Sort By:
Pageof 40
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2021
Immunotherapy use outside clinical trial populations: never say never?K Rzeniewicz, J Larkin, A M Menzies, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2016
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanomaL Spain, R Higgins, K Gopalakrishnan, et al.Journal of Endocrinological Investigation|May 26, 2020
Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSHM S Siddiqui, Z M Lai, L Spain, et al.Clinical and Experimental Dermatology|October 3, 2020
Cutaneous toxicities in patients with melanoma receiving checkpoint inhibitor therapy: a retrospective review. The experience of a single large specialist institutionC L Edwards, F Comito, S Agraso Busto, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literatureL Spain, G Walls, M Julve, et al.ESMO Open|May 17, 2025
Fatal intracranial haemorrhage shortly after belzutifan initiation in von Hippel-Lindau (VHL) disease-associated haemangioblastomaS T C Shepherd, C Kelly-Morland, S Drage, et al.British Journal of Cancer|September 30, 2010
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicineM Gerlinger, C SwantonBritish Journal of Cancer|April 16, 2009
Molecular classification of solid tumours: towards pathway-driven therapeuticsC Swanton, C CaldasAnnals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2014
Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibitionS Turajlic, S J Furney, G Stamp, et al.Immuno-Oncology Technology|July 24, 2023
Immuno-oncology approaches in uveal melanoma: tebentafusp and beyondC Gerard, B Shum, P Nathan, et al.Pageof 40